Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
Crossref DOI link: https://doi.org/10.1186/s12943-017-0662-3
Published Online: 2017-05-30
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ricci, Francesca
Guffanti, Federica
Damia, Giovanna
Broggini, Massimo
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG-12915)